Superior risk stratification for earlier shared decision-making

OncoIntelligenceTM, our proprietary AI-digital pathology platform, reports the first AI-Grade for breast cancer.

Woman with dark wavy hair and a grey scarf looking calmly at the camera

Our mission at PreciseDx® is to deliver objective, accurate and reliable reporting of key clinical information in hours, to improve comprehensive decision-making for patients affected by cancer worldwide.

2.3 million women worldwide are affected by breast cancer every year¹. Standard histologic grading initiates the care pathway yet is inadequate, requiring reliance on further testing. Much of the world’s population lacks access to innovative breast cancer technologies resulting in suboptimal outcomes and poor quality of life.

Until Now+

PreciseBreast, created to standardize cancer care, eliminates the subjectivity and variability of histologic grade. Specific tumor morphology features are analyzed; results enable earlier assessment of recurrence risk and the likelihood of chemotherapy benefit²

For Shared Decision-Making+

PreciseBreast, designed for digitized specimen transfer from any region of the world, reduces logistical and financial barriers while delivering an objective, accurate and reliable AI-Grade in hours.

When Time is of the Essence+

The Problem

Histologic grade, a leading factor to determine prognosis

The use of subjective grading alone is discouraged.⁴ Levels of inter-observer variation can and should still be improved.⁵ Histologic grade includes pathologist-assigned tubule formation, nuclear pleomorphism, and mitotic count. Grading variability may have influenced adjuvant chemotherapy decisions in 30% of patients.⁶ ⁹

50-60%

of breast tumors are categorized as Grade 2⁷

57-70%

pathologist inter & intra-observer variation⁷ ⁸

54.7%

of Grade 3 tumors are low risk²

25.9%

of Grade 2 tumors are high risk²

74.1%

of Grade 2 tumors are low risk²

1 in 8 women will be diagnosed with breast cancer in their lifetime

THE SOLUTION

PreciseBreast AI-Grade provides objective 10-year risk of distant recurrence2

OncoIntelligence assigns AI-Grade based on 7 morphologic features quantified and weighted in the algorithm:¹⁰

1.Tubule formation
2.Nuclear pleomorphism
3.Mitotic density
4.Tumor Infiltrating Lymphocytes (TILs)
5.Tumor/Stroma Ratio
6.Sheets
7.Neighboring Nuclei
Outcome in
48 hrs
✓Accurate, objective risk of recurrence
✓Predicts individual 10-year distant recurrence risk
✓Reports chemotherapy benefit
Learn more about PreciseBreast® →

The results

Spread the news fast

PreciseBreast® provides objective and reliable risk stratification in hours, allowing oncologists to confidently discuss results earlier, in hours, to relieve patient anxiety and to allow for a more comprehensive shared decision-making process.

See more

who we serve

Who PreciseBreast® Benefits

PreciseBreast® powers the process of diagnosis and cancer care planning for everyone.

Medical society partners

Key Partners

We are proud to work with some of the most important cancer associations and societies.

Let’s talk

Please fill out the form below.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.